Pittsburgh, PANCT07275905Now EnrollingIRB Ready

Cystic Fibrosis (CF) Clinical Trial in Pittsburgh, PA

Access cutting-edge cystic fibrosis (cf) treatment through this phase 1 clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Ghady Haidar

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access cystic fibrosis (cf) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cystic fibrosis (cf) treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this cystic fibrosis (cf) clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Cystic Fibrosis (CF) Study in Pittsburgh

The goal of this clinical trial is to learn if a new treatment called AchromoPhage is safe and well tolerated in adults with cystic fibrosis (CF) who have long-term lung infections caused by Achromobacter bacteria. AchromoPhage is a mixture of four naturally occurring viruses, called phages, that are designed to target and kill Achromobacter. This study will include 12 participants. People will be randomly assigned to one of three groups to receive AchromoPhage in different ways: by inhalation only, by intravenous (IV) infusion only, or by inhalation followed by IV infusion. Participants will: * Receive the study drug during clinic visits over a period of three weeks. * Provide blood, sputum, nasal, and oral samples so researchers can measure how the phages move through the body, how long they stay, and whether the body develops a response against them. * Complete breathing tests and quality-of-life questionnaires. The main question this study will answer is whether AchromoPhage causes any serious or treatment-limiting side effects in the first 42 days after dosing. Researchers will also look at changes in lung function, quality of life, phage levels in the body, and how the treatment affects Achromobacter and other bacteria in the lungs. The study is being run at the University of Pittsburgh (Pittsburgh, PA) and the University of California San Diego (San Diego, CA).

Sponsor: Ghady Haidar

Who Can Participate

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Adults of any gender, age 18 years or greater at the time of enrollment.
Weight of 40 kg or greater.
Diagnosed with cystic fibrosis (CF).
Stable respiratory symptoms within 30 days prior to screening.
Chronic Achromobacter respiratory infection, defined as isolation by culture of Achromobacter species from two or more respiratory, oral, and/or nasopharyngeal samples provided by the participant within 24 months before the date of pre-screening.
At least one Achromobacter isolate cultured from a respiratory, oral, and/or nasopharyngeal sample provided by the participant no more than 60 days before the date of planned enrollment must be susceptible to at least 1 phage in AchromoPhage cocktail using study assays.
FEV1 ≥ (greater than or equal to) 40% of predicted at time of screening
Ability and willingness to provide informed consent or, if applicable, the ability and willingness of legal guardian/representative to provide informed consent.
Willingness to comply with study procedures.
Ability to travel to the University of Pittsburgh or the University of California San Diego for phage administration and in-person visits.
Agreement not to enroll in other bacteriophage studies or receive bacteriophages for clinical care during the study, except in life-saving situations.
For females of reproductive potential, a negative urine pregnancy test at the time of consent (before randomization and dosing).
Willingness to use highly effective contraception or other preventive measures to avoid conception during the study and for 6 months after the last phage dose. Note, criteria 5 and 6 are the microbiologic criteria.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:
Serious medical illness requiring systemic treatment or hospitalization within 30 days prior to screening (unless medically stable and approved by the PI).
Acute pulmonary exacerbation requiring systemic antibiotics within 30 days prior to screening.
Acute respiratory illness, including viral infection, within 30 days prior to screening.
Grade 3 or higher alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at or within 30 days prior to screening, defined as ALT or AST values \>5.0 x upper limit of normal (ULN).
Currently breastfeeding, pregnant, or planning to become pregnant within 6 months.
Hemoglobin \< 8 g/dL
Absolute neutrophil count \< 1000 cells/uL
Intolerance to inhaled therapies.
Known allergy or sensitivity to components of the AchromoPhage cocktail.
Any other condition that, in the PI's opinion, would interfere with the conduct of the study or would not be in the participant's best interest.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT07275905) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cystic Fibrosis (CF) Treatment Options in Pittsburgh, PA

If you're searching for cystic fibrosis (cf) treatment options in Pittsburgh, PA, this clinical trial (NCT07275905) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced cystic fibrosis (cf) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cystic fibrosis (cf) clinical trials near you to find additional studies recruiting in your area.

More Cystic Fibrosis Trials in Pittsburgh, PA

See all cystic fibrosis clinical trials recruiting in Pittsburgh — not just this study.

Browse Cystic Fibrosis Trials in Pittsburgh →

Browse More Trials by Condition

Cystic Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA